Sacks Natalie 4
4 · Harpoon Therapeutics, Inc. · Filed Apr 17, 2020
Insider Transaction Report
Form 4
Sacks Natalie
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2020-04-17$2.12/sh+1,021$2,165→ 46,775 total - Exercise/Conversion
Employee Stock Option (right to buy)
2020-04-16−500→ 48,168 totalExercise: $2.12Exp: 2028-11-16→ Common Stock (500 underlying) - Exercise/Conversion
Common Stock
2020-04-16$2.12/sh+500$1,060→ 46,254 total - Exercise/Conversion
Employee Stock Option (right to buy)
2020-04-17−1,021→ 47,147 totalExercise: $2.12Exp: 2028-11-16→ Common Stock (1,021 underlying) - Sale
Common Stock
2020-04-16$12.00/sh−500$6,000→ 45,754 total - Sale
Common Stock
2020-04-17$12.08/sh−1,021$12,330→ 45,754 total
Footnotes (3)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- [F2]Represents the weighted average sales price per share. The shares sold at prices ranging from $12.00 to $12.15 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- [F3]The stock option vested and became exercisable as to 25% of the shares subject to the option on November 16, 2019, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.